Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise
Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.
Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug
As the effectiveness of in-person detailing wanes, how will cloud-based content solutions adapt?
To break through and drive a high level of physician interaction, Havas Life Metro and Genentech created an interactive self-guided digital storytelling experience to explain the unique mechanism of action of Gazyva.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.
Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin
Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures
Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Merck's DTC ad for Keytruda hints at more cancer brands turning to TV
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Five things for pharma marketers to know: Wednesday, February 15, 2017